Chongqing Precision Biotech Co., Ltd: all 51 studies

Page 1 of 1. Open to participants first (37), then studies with results posted, then the rest; newest registration first within each.

• In Vivo PICX CAR-T Therapy for R/R Multiple MyelomaRecruitingNCT07715630Phase 1
• Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07637929
• PIC1 Injection Therapy for Relapsed/Refractory B-NHLRecruitingNCT07456371Phase 1
• Study of CD19 CAR-T Therapy for Refractory SLERecruitingNCT07403097Phase 1
• Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLERecruitingNCT07331467Phase 1
• Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLERecruitingNCT07318259Phase 1
• In VIVO CAR-T Therapy for Relapsed/Refractory Hematological MalignanciesRecruitingNCT07239323Phase 1
• Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic DiseasesRecruitingNCT07184450Phase 1
• CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid TumorsRecruitingNCT07179692Phase 1
• Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung CancerRecruitingNCT06992583Phase 1
• Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung CancerRecruitingNCT06945523Phase 1
• Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic MalignanciesRecruitingNCT06909474Phase 1
• Anti-CEA CAR-T for Advanced CEA-Positive Lung CarcinomaRecruitingNCT06903117Phase 1
• Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLERecruitingNCT06892145Phase 1
• A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung CancerRecruitingNCT06768151Phase 1
• Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCNRecruitingNCT06690827Phase 1
• Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)RecruitingNCT06686524Phase 1
• Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALLNot yet recruitingNCT06641024Phase 1
• Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile DermatomyositisRecruitingNCT06569472Phase 1
• A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic CancerRecruitingNCT06215950Phase 1
• Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell LymphomaRecruitingNCT06180174Phase 1
• Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid TumorsRecruitingNCT06126406Phase 1
• Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune DiseaseRecruitingNCT06056921Phase 1
• A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid TumorsRecruitingNCT06043466Phase 1
• A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid TumorsRecruitingNCT06010875Phase 1
• Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid TumorsRecruitingNCT06010862Phase 1
• CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid TumorsRecruitingNCT06006390Phase 1/2
• A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-TRecruitingNCT05468190Phase 1
• A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid TumorsRecruitingNCT05420545Phase 1
• Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal CancerRecruitingNCT05420519Phase 1
• Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin LymphomaRecruitingNCT05420493Phase 1
• A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRecruitingNCT05334823Phase 2
• A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALLRecruitingNCT04781634Phase 1/2
• A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseRecruitingNCT04776330Phase 1/2
• Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT04272125Phase 1/2
• BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseRecruitingNCT04271644Phase 1/2
• CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/2
• CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid TumorsSuspendedNCT07181720Phase 1
• Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmCompletedNCT06006403Phase 1/2
• Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid TumorsCompletedNCT05538195Phase 1/2
• Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid TumorsCompletedNCT05415475Phase 1
• Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsCompletedNCT04888468Phase 1
• Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALLStatus unknownNCT04888442Phase 1
• Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple MyelomaStatus unknownNCT04861480Phase 1
• a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell LymphomaStatus unknownNCT04782193Phase 1/2
• CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04649983Phase 1/2
• Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04648475Phase 1/2
• Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ CancerWithdrawnNCT04348643Phase 1/2
• Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple MyelomaStatus unknownNCT04272151Phase 1/2
• Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaStatus unknownNCT04271800Phase 1/2
• CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04265963Phase 1/2

← Chongqing Precision Biotech Co., Ltd overview and focus areas